Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > September 21, 2022
Daily News
September 21, 2022
- Sales Reps in Japan Decrease for 8 Years Straight as Voluntary Redundancy Weighs: FY2021 Report
September 21, 2022
- Japan Healthcare Spending Logs 44.2 Trillion Yen in FY2021, Up 4.6% on Post-Pandemic Rebound
September 21, 2022
- LDP OKs Draft Bill to Amend Infectious Disease Act to Enable Requests for Vaccine Production Boost in Emergencies
September 21, 2022
- 2 Years after Full Rollout, Sakigake System Shows Tepid Uptake as Industry Sees Poor Incentives
September 21, 2022
- UCB’s Epilepsy Drug Brivaracetam Hits PIII Goal, Japan Submission Eyed in 2023
September 21, 2022
- Otsuka’s Lupus Nephritis Med Lupkynis Wins European Greenlight
September 21, 2022
- Takeda’s CMV Drug Maribavir Snags EU Panel Backing
September 21, 2022
- MHLW Retools New Expert Panel, Industry Hearing Set for Sept. 22
September 21, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…